NOD/ShiLtJGpt-Prkdc^em26Cd52Il2rg^em26Cd22/Gpt

NCG|Strain NO.T001475

Knockout (KO)

Product Type:
Quantity: - +
Sex:
Age:
Genotype:

BASIC INFORMATION

Strain Name:	NOD/ShiLtJGpt-Prkdc^em26Cd52Il2rg^em26Cd22/Gpt
Strain Number:	T001475
Official Symbol:	Prkdc,Il2rg
Strain Strategy:	T001475.NCG strain info.pdf
Official Full Name:	protein kinase DNA activated catalytic polypeptide,interleukin 2 receptor gamma chain
Also Known As:	AI326420,AU019811,DNA-PKcs,DNAPDcs,DNAPK,DNPK1,DOXNPH,HYRC1,XRCC7,dxnph,p460
NCBI Number:	19090 16186
MGI Number:	104779 96551
Research Areas:	Humanized model,Humanization of the immune system,Immunodeficiency
Strain Background:	[N000235] NOD/ShiLtJGpt
Modification Type:	Knockout (KO)
Inventory Status:	Live,Cryopreserved
Sale Status:	IF (Available for Distribution)
Health Status:	Specific pathogen free (SPF)
Health Report:	Please log in to view
Publications:	1. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment 2. Cytoplasmic NEAT1 Suppresses AML Stem Cell Self‐Renewal and Leukemogenesis through Inactivation of Wnt Signaling 3. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML 4. Biomimetic Nanoerythrosome‐Coated Aptamer‐DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐positive Breast Cancer 5. Interferon-a potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment 6. Autologous transplantation of thecal stem cells restores ovarian function in nonhuman primates 7. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3 8. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1 9. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling 10. Creatine promotes cancer metastasis through activation of Smad2/3 11. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells 12. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia 13. Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors 14. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy 15. The Rational Development of CD5-targeting Biepitopic Chimeric Antigen Receptors with Fully Human Heavy-chain-only Antigen Recognition Domains 16. N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression 17. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors 18. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression 19. ARID1A prevents squamous cell carcinoma initiation and chemoresistance by antagonizing pRb/E2F1/c-Myc-mediated cancer stemness 20. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy 21. Dendrimer-Functionalized Superparamagnetic Nanobeacons for Real-Time Detection and Depletion of HSP90α mRNA and MR Imaging 22. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study 23. OXTR(High) stroma fibroblasts control the invasion pattern of oral squamous cell carcinoma via ERK5 signaling 24. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL 25. Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer 26. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma 27. Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy 28. Targeting ARF1-IQGAP1 interaction to suppress colorectal cancer metastasis and vemurafenib resistance 29. Hook&Loop multivalent interactions based on disk-shaped nanoparticles strengthen active targeting 30. Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy 31. BPA‐Containing Polydopamine Nanoparticles for Boron Neutron Capture Therapy in a U87 Glioma Orthotopic Model 32. Anti-BCMA surface engineered biomimetic photothermal nanomissile enhances multiple myeloma cell apoptosis and overcomes the disturbance of NF-kappaB signaling in vivo 33. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1 34. Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche 35. Supramolecular nanofibers co-loaded with dabrafenib and doxorubicin for targeted and synergistic therapy of differentiated thyroid carcinoma 36. PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance 37. Impaired histone inheritance promotes tumor progression 38. NOTCH4(DeltaL12_16) sensitizes lung adenocarcinomas to EGFR-TKIs through transcriptional down-regulation of HES1 39. Targeting Trop2 by Bruceine D suppresses breast cancer metastasis by blocking Trop2/beta-catenin positive feedback loop 40. GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer 41. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRbeta complex in hepatocellular carcinoma 42. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment 43. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models 44. Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma 45. Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma 46. Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin 47. WDR54 exerts oncogenic roles in T-cell acute lymphoblastic leukemia 48. Activation of melanocortin-1 receptor signaling in melanoma cells impairs T cell infiltration to dampen antitumor immunity 49. Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells 50. The application of HER2 and CD47 CAR-macrophage in ovarian cancer 51. A drug-delivery depot for epigenetic modulation and enhanced cancer immunotherapy 52. A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options 53. Intratumoral CD103(+) CD8(+) T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma 54. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression 55. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer 56. Enhancement of the viability of T cells electroporated with DNA via osmotic dampening of the DNA-sensing cGAS-STING pathway 57. Lipid accumulation-mediated histone hypoacetylation drives persistent NK cell dysfunction in anti-tumor immunity 58. Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models 59. GARP-mediated active TGF-beta1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT 60. Long noncoding RNA NONHSAT160169.1 promotes resistance via hsa-let-7c-3p/SOX2 axis in gastric cancer 61. Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51 62. Tumor-infiltrating platelets promote the growth of lung adenocarcinoma 63. Carboxypeptidase A4 negatively regulates HGS-ETR1/2-induced pyroptosis by forming a positive feedback loop with the AKT signalling pathway 64. Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application 65. Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma 66. Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma 67. A Near-Infrared-II Fluorescent Nanocatalyst for Enhanced CAR T Cell Therapy against Solid Tumor by Immune Reprogramming 68. Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity 69. IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects 70. FKBP10 promotes clear cell renal cell carcinoma progression and regulates sensitivity to the HIF2alpha blockade by facilitating LDHA phosphorylation 71. Enhanced Precision Therapy of Multiple Myeloma Through Engineered Biomimetic Nanoparticles with Dual Targeting 72. Cell-Surface GRP78-Targeted Chimeric Antigen Receptor T Cells Eliminate Lung Cancer Tumor Xenografts 73. An Anti-CD7 Antibody-Drug Conjugate Target Showing Potent Antitumor Activity for T-Lymphoblastic Leukemia (T-ALL)74. Effects of methionine deficiency on B7H3-DAP12-CAR-T cells in the treatment of lung squamous cell carcinoma 75. Endoplasmic reticulum aminopeptidase 2 regulates CD4(+) T cells pyroptosis in rheumatoid arthritis 76. RNA-binding protein RBM5 plays an essential role in acute myeloid leukemia by activating the oncogenic protein HOXA9 77. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3/CD28 co-engagement 78. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma 79. RORalpha is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis 80. High-fat diet promotes prostate cancer metastasis via RPS27